Samsung Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Samsung Pharmaceutical is listed on KOSPI and classified under Health Care, Pharmaceuticals. Its market value is US$92M. In FY2025 it reported revenue of US$34.8M and an operating loss of US$13.6M.
A written company profile is not available yet; the facts above come from exchange and DART data.
Samsung Pharmaceutical in five facts
Where is Samsung Pharmaceutical listed and in which sector?
Samsung Pharmaceutical (Korean name: 삼성제약) trades under KRX code 001360 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Samsung Pharmaceutical?
Its market capitalisation was US$92M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Samsung Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Samsung Pharmaceutical reported revenue of US$34.8M, an operating loss of US$13.6M and net income of US$8.7M, per its annual report on DART (data retrieved from DART on 2026-09-05). Revenue was up 4.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-05
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Material management matter relevant to investment decisionsSep 28
- Material management matter relevant to investment decisionsSep 23
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Sep 11
- Material event report (convertible bonds)
Samsung Pharmaceutical disclosed convertible bonds to raise US$4.42M, about 4.4% of its market value.
Capital raise · Sep 2 - Material event report (decision to redeem own convertible bonds early)
Samsung Pharmaceutical Co., Ltd. resolved on 2026-08-12 to acquire US$14.3M face value of its 32nd-series convertible bonds early, for US$14.6M, following bondholders' exercise of early-redemption (put) rights and negotiated transfers, leaving US$4.71M face value outstanding.
Capital raise · Aug 12 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Samsung Pharmaceutical reported separate results for FY2025: revenue of US$31.5M (+4.02% year on year), an operating loss of US$12.4M and net income of US$8.3M (from a loss a year earlier).
Earnings · Feb 9 - Material event report (CB call option holder designated)Capital raise · Jan 16